Skip to main content
Top
Published in: Diabetologia 11/2010

01-11-2010 | Letter

Cholesterol toxicity in pancreatic islets from LDL receptor-deficient mice. Reply to: de Souza JC, de Oliveira CAM, Carneiro EM et al. [letter]

Authors: J. K. Kruit, L. R. Brunham, C. B. Verchere, M. R. Hayden

Published in: Diabetologia | Issue 11/2010

Login to get access

Excerpt

To the Editor: In their letter [1], de Souza and colleagues point out important differences between our study [2] and their subsequent report on the role of the LDL receptor (LDLr) in islet cholesterol handling. In contrast to their data [3], we did not detect a significant difference between islet cholesterol levels in mice lacking LDLr (Ldlr –/–) and control mice [2]. Accordingly, we found no difference in glucose tolerance or insulin secretion in Abca1 fl/fl;Ldlr +/+ mice compared with Abca1 fl/fl;Ldlr–/– mice on a chow diet. This is in agreement with previous literature showing no effect of LDLr deficiency on fasting glucose levels and glucose tolerance in chow-fed mice and slightly improved glucose tolerance in mice fed a Western-type diet [4, 5]. At this point the reasons for the discordant results obtained by Bonfleur and colleagues are not clear, as both groups used mice bred on a pure C57Bl6 background at similar ages (16 weeks). However, the results of both groups point to the ability of circulating and cellular cholesterol to significantly influence islet function. …
Literature
1.
2.
go back to reference Kruit JK, Kremer PHC, Dai L, et al. (2010) Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 53: 1110–1119 Kruit JK, Kremer PHC, Dai L, et al. (2010) Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 53: 1110–1119
3.
go back to reference Bonfleur ML, Vanzela EC, Ribeiro RA et al (2010) Primary hypercholesterolaemia impairs glucose homeostasis and insulin secretion in low-density lipoprotein receptor knockout mice independently of high-fat diet and obesity. Biochim Biophys Acta 1801:183–190PubMed Bonfleur ML, Vanzela EC, Ribeiro RA et al (2010) Primary hypercholesterolaemia impairs glucose homeostasis and insulin secretion in low-density lipoprotein receptor knockout mice independently of high-fat diet and obesity. Biochim Biophys Acta 1801:183–190PubMed
4.
go back to reference Coenen KR, Gruen ML, Hasty AH (2007) Obesity causes very low density lipoprotein clearance defects in low-density lipoprotein receptor-deficient mice. J Nutr Biochem 18:727–735CrossRefPubMed Coenen KR, Gruen ML, Hasty AH (2007) Obesity causes very low density lipoprotein clearance defects in low-density lipoprotein receptor-deficient mice. J Nutr Biochem 18:727–735CrossRefPubMed
5.
go back to reference Karagiannides I, Abdou R, Tzortzopoulou A, Voshol PJ, Kypreos KE (2008) Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. FEBS J 275:4796–4809CrossRefPubMed Karagiannides I, Abdou R, Tzortzopoulou A, Voshol PJ, Kypreos KE (2008) Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. FEBS J 275:4796–4809CrossRefPubMed
6.
go back to reference Skoumas I, Masoura C, Pitsavos C et al (2007) Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Int J Cardiol 121:178–183CrossRefPubMed Skoumas I, Masoura C, Pitsavos C et al (2007) Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Int J Cardiol 121:178–183CrossRefPubMed
7.
go back to reference Vohl MC, Gaudet D, Moorjani S et al (1997) Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest 27:366–373CrossRefPubMed Vohl MC, Gaudet D, Moorjani S et al (1997) Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest 27:366–373CrossRefPubMed
8.
go back to reference Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375:735–742CrossRefPubMed Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375:735–742CrossRefPubMed
Metadata
Title
Cholesterol toxicity in pancreatic islets from LDL receptor-deficient mice. Reply to: de Souza JC, de Oliveira CAM, Carneiro EM et al. [letter]
Authors
J. K. Kruit
L. R. Brunham
C. B. Verchere
M. R. Hayden
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1877-7

Other articles of this Issue 11/2010

Diabetologia 11/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.